AtriCure, Inc. Hits New 52-Week High of $44.16, Up 99% Yearly

AtriCure, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 44.16 on August 13, 2026. This achievement marks a remarkable 99.04% increase in the company's stock price over the past year, significantly outperforming the S&P 500, which has seen a gain of 20.6% during the same period. The company's market capitalization stands at USD 1,439 million, reflecting its position within the small-cap segment. AtriCure has demonstrated strong operational performance, with an impressive operating profit growth of 180.02% reported in its latest results on June 26. The company has consistently delivered positive results for the last eight consecutive quarters, showcasing its resilience and operational efficiency. AtriCure's financial metrics further highlight its robust standing, with the highest operating cash flow recorded at USD 64.94 million and a return on capital employed (ROCE) of 2.15%. Additionally, the company boasts high institutional holdings at 100%, indicating strong confidence from institutional investors in its fundamentals.